IBRX vs GILD: Which Stock is Better?
Side-by-side comparison of Immunitybio Inc and Gilead Sciences Inc in 2026
IBRX
Immunitybio Inc
$8.20
GILD
Gilead Sciences Inc
$135.87
Key Metrics Comparison
| Metric | IBRX | GILD | Winner |
|---|---|---|---|
| Market Cap | $7.95B | $170.84B | GILD |
| P/E Ratio | N/A | 20.27 | GILD |
| EPS (TTM) | $N/A | $6.79 | GILD |
| Revenue Growth | 4.1% | 0.0% | IBRX |
| Gross Margin | 99.3% | 78.8% | IBRX |
Analyze IBRX
Full quant analysis
Analyze GILD
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is IBRX or GILD a better investment?
Comparing IBRX and GILD: Immunitybio Inc has a market cap of $7.95B while Gilead Sciences Inc has $170.84B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between IBRX and GILD?
IBRX (Immunitybio Inc) and GILD (Gilead Sciences Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: IBRX or GILD?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: IBRX or GILD?
IBRX has higher revenue growth at 4.1% vs 0.0% for GILD.
Which company is more profitable: IBRX or GILD?
Immunitybio Inc (IBRX) has higher gross margins at 99.3% compared to 78.8% for GILD.
Which is the larger company: IBRX or GILD?
Gilead Sciences Inc (GILD) is larger with a market cap of $170.84B compared to $7.95B for IBRX.
Should I buy IBRX or GILD in 2026?
Both IBRX and GILD have investment merit. IBRX trades at $8.20 while GILD trades at $135.87. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between IBRX and GILD stock?
Key differences: Market Cap ($7.95B vs $170.84B), P/E Ratio (N/A vs 20.3x), Revenue Growth (4.1% vs 0.0%), Gross Margin (99.3% vs 78.8%).